Profits Up At Leciva
- Prague-based company Leciva recorded gross profits of 232 millionkoruna ($8.6 million), a rise of 4.5%, on sales for the year of 1.2 billion koruna, an increase of 5.9% in the first three months of 1997, reports the CTK news agency's Business News.
In 1996, Leciva recorded gross profits of 507 million koruna, and turnover of 4.8 billion koruna. The Czech drug company's shares traded at 2,218 koruna on the Prague Stock Exchange on June 3. Leciva's largest shareholder is the Czech National Property Fund, with a 68.63% stake, according to CTK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze